CellCentric successfully completes InnovateUK programme
CellCentric is developing small molecule inhibitors for the most aggressive form of prostate cancer (CRPC). In March 2013, the company secured support from InnovateUK, combined with venture capital investment, to develop novel small molecule modulators of the androgen receptor pathway. This programme has now completed, on time and on budget.
CellCentric receives patent grants for gene demethylation technology
A European patent award has now been received, in addition to recent US grants, that covers a technology for site specific gene demethylation. This technology can be a useful tool in understanding the epigenetic regulation of cells, and the mechanisms used to control cell fate. This has implications for understanding disease processes and potentially the development of new treatments.
CellCentric gains £4.3m to take prostate cancer programme through to clinical candidates
New investment coupled with a major award from the UK’s innovation agency, the Technology Strategy Board, will provide funding for over two years to conduct lead optimisation and clinical candidate generation on inhibitors against a specific deubiquitinase target, demonstrated to play a key role in the progression of prostate cancer.
CellCentric secures further funding for its Castration Resistant Prostate Cancer Programme
New investment fuels further lead optimisation work on inhibitors against a specific deubiquitinase target. Compounds generated to date effect both native and splice variant androgen receptors, which are key in the progression of the most lethal form of prostate cancer. They offer a clear opportunity to address resistance mechanisms seen with current agents for the disease.
CellCentric and ZoBio enter into partnership to develop lead compounds against epigenetic drug targets
CellCentric and ZoBio are pleased to announce that the companies are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets. ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.
New consortium to investigate epigenetics and metabolic disorders
CellCentric joins a group of leading academic researchers around the world to investigate epigenetic mechanisms underlying diabetes. CellCentric is the sole commercial partner to a new consortium being funded by the European Union. The collaboration may yield new targets for small molecule therapeutics.
CellCentric CEO appointed to BBSRC Council
The Minister for Universities and Science, David Willetts, has appointed three new members to the Council of the Biotechnology and Biological Sciences Research Council (BBSRC)
CellCentric closes first tranche of series B financing
New funding sees CellCentric expand drug discovery activities across multiple epigenetic targets.
CellCentric featured in Nature Biotechnology
A new review of second generation epigenetic targets highlights CellCentric as a key leader in a field which is becoming a strategic research and development imperative for many pharmaceutical companies.
CellCentric publishes on non-oncology indications
CellCentric’s Scientific Director Nessa Carey and Programme Manager Jonathan Best publish a review on epigenetics and non-oncology therapeutic indications in Drug Discovery Today.